Lupus & antiphospholipid syndrome
Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis
Authors' conclusion
This study demonstrates that persistent IFN-I-driven gene expression in monocytes characterises treatment resistance in LN.
Study context
- Population
- Patients with biopsy-proven active proliferative lupus nephritis (LN), Korean Unlimited multi-Dimensional Omics research in SLE cohortscRNA-seq n = 10
- Comparison
- Complete responders vs nonresponders to standard-of-care induction therapy
Methodological detailslongitudinal, single-cell RNA sequencing, independent validation cohort (bulk RNA sequencing of monocytes)
- Longitudinal
- Single-cell RNA sequencing
- Independent validation cohort (bulk RNA sequencing of monocytes)
Main finding
As reported in the abstract
- Myeloid cells, particularly classical and intermediate monocytes, had the highest number of differentially expressed genes after induction therapy
- Complete responders: progressive suppression of IFN-I signalling; nonresponders: persistent IFN-I-driven gene expression with sustained inflammatory features
- Validation: 6 IFN-I-responsive genes (IRF7, ISG15, LY6E, IFI44, IFI44L, IFI6) significantly downregulated by 3 months in complete responders, not in nonresponders
- Gene signature correlated with proteinuria and disease activity scores
Original publication
Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis. Ann Rheum Dis. Published 2 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →